Biocredit Antigen Test

VITROS SARS CoV2 Antigen CLIA based Examine

Description

Lateral motion immunochromatographic assay that adopted twin color system.
For the qualitative detection of SARS-CoV-2 antigen from nasopharyngeal swab specimen.
The verify incorporates colloid gold conjugate pad and a membrane strip pre-coated with antibodies specific to SARS-CoV-2 antigen on the verify traces (T).
A visible black band (antibody-antigen-antibody gold conjugate sophisticated) appears on the verify traces (T) If SARS-CoV-2 antigen is present throughout the specimen.
The administration line (C) reveals that verify is carried out appropriately.
Evaluated with panel specimen (n = 75) by PCR
Sensitivity: 90,2 %
Specificity: 100 %

Diagnostics

1. The VITROS SARS CoV2 Antigen assay is a chemiluminescent immunoassay meant for the qualitative
detection of SARS-CoV-2 nucleocapsid antigens in nasopharyngeal (NP) specimens from individuals who
are suspected of COVID-19 inside one to five days of the onset of indicators, or mid-turbinate specimens
collected from asymptomatic individuals.
2. The assay must be carried out in VITROS 3600 Immunodiagnostics system or VITROS 5600 / VITROS XT 7600
Constructed-in system from Ortho.

Features

COVID-19, Nasopharyngeal swabs

 

SKU:G61RHA20

AVAILABILITY:In Stock with The Lowest Value throughout the Market

SHIPMENT:Related Day Cargo Orders Sooner than 14

H00SIZE:20 Exams/KitSPECIFICITY:98.90%

Type

Immunochromatography speedy verify

Biocredit Rapigen One Step Rapid Test
Biocredit Rapigen One Step Rapid Test

Guidance for use of VITROS SARS CoV2 Antigen CLIA based Examine from Ortho Medical

Calibration Differ

Qualitative

VITROS SARS CoV2 antigen assay – Procedural Steps: –

Stage 1: Nasopharyngeal swab specimen assortment:
1. Purchase a nasopharyngeal swab specimen by inserting the sterile swab into the nostril.
2. Push the sterile swab until resistance is met on the stage of the turbinate.
3. Rotate the sterile swab plenty of events in direction of the nasopharyngeal wall & go away throughout the place for
10 seconds to saturate the swab tip.
4. Take away the swab from the nostril fastidiously.
5. Place the swab specimen into the viral transport medium buffer tube and shut the tube tightly.
6. Transport the swab sample in VTM to the laboratory in a cold chain.
7. The sample may very well be saved in Room temperature (Beneath 30◦C) for as a lot as 24 hrs from the time of
sample assortment or at 2 – 8◦C for as a lot as 48 hrs from the time of sample assortment.

Stage 2: Sample preparation for testing:

1. Sample preparation should be carried out in BSL-2 stage cabinet throughout the Laboratory.
2. Mix the swab specimen in VTM tube properly (vortex roughly 3-5 seconds).
3. Change 100 μL VITROS SARS-CoV-2 Antigen Extraction Buffer proper right into a labelled new sample tube.
4. Add 400 μL viral sample to the above tube (to deal with 1:4 ratio of extraction buffer: sample)
5. Mix properly (Cap/Plug the sample tube and vortex roughly 3-5 seconds).

COVID-19 IgG/IgM Rapid Test Kit

UNCOV-20 20T/kit
EUR 155
Description: COVID-19 IgG/IgM Rapid Test (Serum/Plasma/Whole Blood) is a qualitative membrane-based immunoassay for the detection of COVID-19 antibodies in serum, plasma, or whole blood. This test consists of two test lines, an IgG line and an IgM line, which is pre-coated with two mouse anti-human monoclonal antibodies separately. During testing, the sample reacts with COVID-19 antigen-coated on conjugated pad. As the complex continues to travel up the strip, the anti-COVID-19 IgM antibodies are bound on the IgM line, and the anti-COVID-19 IgG antibodies are bound on the IgG line. The control(C)line appears when sample has flowed through the strip. The presence of anti-COVID-19 IgM and/or IgG will be indicated by a visible test line in the IgM and IgG region. To serve as a procedural control, the control line should always appear if the test procedure is performed properly and the reagents are working as intended.

SARS-CoV-2 (COVID-19) Spike Antibody

3525-002mg 0.02 mg
EUR 171.82
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike Antibody

3525-01mg 0.1 mg
EUR 436.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Envelope Antibody

3531-002mg 0.02 mg
EUR 171.82
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).

SARS-CoV-2 (COVID-19) Envelope Antibody

3531-01mg 0.1 mg
EUR 436.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).

SARS-CoV-2 (COVID-19) NSP7 Peptide

9155P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP7 Peptide

SARS-CoV-2 (COVID-19) Membrane Peptide

9157P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Membrane Peptide

SARS-CoV-2 (COVID-19) NSP8 Peptide

9159P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide

SARS-CoV-2 (COVID-19) NSP9 Peptide

9161P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide

SARS-CoV-2 (COVID-19) NSP9 Peptide

9163P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide

SARS-CoV-2 (COVID-19) Membrane Peptide

9165P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Membrane Peptide

SARS-CoV-2 (COVID-19) NSP8 Peptide

9167P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide

SARS-CoV-2 (COVID-19) Envelope Peptide

9169P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Envelope Peptide

SARS-CoV-2 (COVID-19) NSP2 Peptide

9171P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide

SARS-CoV-2 (COVID-19) NSP2 Peptide

9173P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide

SARS-CoV-2 (COVID-19) NSP4 Peptide

9175P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP4 Peptide

SARS-CoV-2 (COVID-19) NSP6 Peptide

9177P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP6 Peptide

SARS-CoV-2 (COVID-19) NSP10 Peptide

9179P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP10 Peptide

SARS-CoV-2 (COVID-19) ORF6 Peptide

9189P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF6 Peptide

SARS-CoV-2 (COVID-19) ORF9b Peptide

9191P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF9b Peptide

SARS-CoV-2 (COVID-19) ORF3a Peptide

9275P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF3a Peptide

SARS-CoV-2 (COVID-19) ORF3b Peptide

9277P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide

SARS-CoV-2 (COVID-19) ORF3b Peptide

9279P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide

SARS-CoV-2 (COVID-19) ORF3b Peptide

9281P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF3b Peptide

SARS-CoV-2 (COVID-19) ORF7a Peptide

9283P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF7a Peptide

SARS-CoV-2 (COVID-19) ORF7a Peptide

9285P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF7a Peptide

SARS-CoV-2 (COVID-19) ORF8 Peptide

9287P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide

SARS-CoV-2 (COVID-19) ORF8 Peptide

9289P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide

SARS-CoV-2 (COVID-19) ORF9c Peptide

9291P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF9c Peptide

SARS-CoV-2 (COVID-19) ORF10 Peptide

9293P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) ORF10 Peptide

SARS-CoV-2 (COVID-19) Nucleocapsid Antibody

9099-002mg 0.02 mg
EUR 191.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2). Nucleocapsid (N) protein is the most abundant protein of coronavirus. It is also one of the major structural proteins and is involved in the transcription and replication of viral RNA, packaging of the encapsidated genome into virions (3), and interference with cell cycle processes of host cells (4). Moreover, in many coronaviruses, including SARS-CoV, the N protein has high immunogenic activity and is abundantly expressed during infection (5). It can be detected in various patient samples including nasopharyngeal aspirate, urine, and fecal. Both S and N proteins may be potential antigens for serodiagnosis of COVID-19, just as many diagnostic methods have been developed for diagnosing SARS based on S and/or N proteins (6).

Leave a Reply

Your email address will not be published.